Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M149,916Revenue $M24,890Net Margin (%)48.6Z-Score7.8
Enterprise Value $M152,585EPS $7.4Operating Margin %61.3F-Score8
P/E(ttm))13.6Cash Flow Per Share $4.3Pre-tax Margin (%)59.7Higher ROA y-yY
Price/Book9.910-y EBITDA Growth Rate %0Quick Ratio2.8Cash flow > EarningsY
Price/Sales6.75-y EBITDA Growth Rate %27.2Current Ratio3.1Lower Leverage y-yN
Price/Cash Flow17.4y-y EBITDA Growth Rate %246ROA % (ttm)41.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)86.6Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M1,489ROI % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDKen Heebner 2014-12-31 Sold Out -4.7%$89.45 - $114.22
($103.4)
$ 100.66-3%Sold Out0
GILDJulian Robertson 2014-12-31 Add1.67%$89.45 - $114.22
($103.3)
$ 100.66-3%Add 20.27%533,911
GILDLeon Cooperman 2014-12-31 Buy 0.96%$89.45 - $114.22
($103.54)
$ 100.66-3%New holding612,500
GILDJean-Marie Eveillard 2014-12-31 Add0.3%$89.45 - $114.22
($103.4)
$ 100.66-3%Add 328672.00%1,315,088
GILDJoel Greenblatt 2014-12-31 Add0.26%$89.45 - $114.22
($103.3)
$ 100.66-3%Add 51.98%1,009,462
GILDRonald Muhlenkamp 2014-12-31 Add0.24%$89.45 - $114.22
($103.4)
$ 100.66-3%Add 6.10%218,945
GILDJohn Rogers 2014-12-31 Add0.17%$89.45 - $114.22
($103.4)
$ 100.66-3%Add 24.68%802,803
GILDVanguard Health Care Fund 2014-12-31 Sold Out -0.1%$89.45 - $114.22
($103.4)
$ 100.66-3%Sold Out0
GILDMariko Gordon 2014-12-31 Sold Out -0.05%$89.45 - $114.22
($103.3)
$ 100.66-3%Sold Out0
GILDDavid Dreman 2014-12-31 Sold Out -0.02%$89.45 - $114.22
($103.3)
$ 100.66-3%Sold Out0
GILDRonald Muhlenkamp 2014-09-30 Add1.19%$85.07 - $109.43
($97.98)
$ 100.663%Add 42.59%206,350
GILDKen Heebner 2014-09-30 Reduce-0.33%$85.07 - $109.43
($97.98)
$ 100.663%Reduce -8.77%1,560,000
GILDVanguard Health Care Fund 2014-09-30 Reduce-0.28%$85.07 - $109.43
($97.98)
$ 100.663%Reduce -76.79%379,200
GILDJoel Greenblatt 2014-09-30 Add0.21%$85.07 - $109.43
($97.98)
$ 100.663%Add 42.28%664,223
GILDKen Fisher 2014-09-30 Reduce-0.04%$85.07 - $109.43
($97.98)
$ 100.663%Reduce -21.74%763,423
GILDDavid Dreman 2014-09-30 Buy 0.02%$85.07 - $109.43
($97.98)
$ 100.663%New holding2,388
GILDDodge & Cox 2014-09-30 Buy $85.07 - $109.43
($97.98)
$ 100.663%New holding4,800
GILDKen Heebner 2014-06-30 Buy 3.8%$65.48 - $83.02
($77.76)
$ 100.6623%New holding1,710,000
GILDJulian Robertson 2014-06-30 Add2.98%$65.48 - $83.02
($77.76)
$ 100.6623%Add 28.55%443,911
GILDRonald Muhlenkamp 2014-06-30 Reduce-0.59%$65.48 - $83.02
($77.76)
$ 100.6623%Reduce -24.63%144,715
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Alton Gregg HEVP, Corp & Med Affairs 2015-04-08Sell5,000$1003.72view
Carter Paul RutherfordEVP Commercial Ops 2015-04-08Sell1,000$1003.72view
MARTIN JOHN CChairman and CEO 2015-04-01Sell150,000$96.747.22view
Alton Gregg HEVP, Corp & Med Affairs 2015-04-01Sell7,000$96.537.45view
Carter Paul RutherfordEVP Commercial Ops 2015-04-01Sell1,000$98.045.79view
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2015-03-16Sell70,000$100.82.9view
Whitley Richard JamesDirector 2015-03-02Sell5,000$103.430.28view
Alton Gregg HEVP, Corp & Med Affairs 2015-03-02Sell12,000$103.630.09view
MARTIN JOHN CChairman and CEO 2015-03-02Sell150,000$103.510.2view
Carter Paul RutherfordEVP Commercial Ops 2015-03-02Sell2,000$104.18-0.44view

Press Releases about GILD :

    Quarterly/Annual Reports about GILD:

    News about GILD:

    Articles On GuruFocus.com
    Prescription Data Offers Insight Into Gilead Sciences' Sales Apr 08 2015 
    HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 
    Weekly CEO Sells Highlight: Sprouts Farmers Market, Lions Gate Entertainment, AMN Healthcare Service Apr 05 2015 
    My starred stocks Apr 05 2015 
    sales growth Apr 03 2015 
    Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
    UnitedHealth Planning Catamaran Corp’s Acquisition For $12.78 Billion Apr 02 2015 
    Gilead’s Hep C Drug Receives Approval in Japan Mar 31 2015 
    Analysts Remain Bullish on Gilead Despite Safety Warning Mar 24 2015 
    interested Mar 22 2015 

    More From Our Partners
    Q1 Earnings Season Ramps Up - Earnings Preview Apr 13 2015 - ZACKS

    More From Other Websites
    Q1 Earnings Season Ramps Up - Earnings Preview Apr 13 2015
    5 Companies the crowd is betting on to beat Wall Street Apr 13 2015
    Biotech: Making sense of the science Apr 13 2015
    Midday Glance: Biotechnology companies Apr 13 2015
    AbbVie Upgraded On $7.8 Billion Imbruvica Potential Apr 13 2015
    Short Sellers Increase Their Bets Against Biotech Stocks Apr 13 2015
    How tech commercialization could pay off big for Johns Hopkins Apr 13 2015
    Gilead combats wider distribution of cheap drugs from EM Apr 12 2015
    Why Merck's Victory Is of Little Concern to Gilead Apr 10 2015
    Stocks Up For Second Week As GE Soars Apr 10 2015
    Biotech Investors: Nomura Says To Watch These Dates Apr 10 2015
    5 stocks to beat the street Apr 10 2015
    Stock Market News for April 10, 2015 - Market News Apr 10 2015
    Gilead: Little Hep C Competition, But What About Pricing? Apr 10 2015
    The Oprahs Of Biotech: People Who Can Go By First Name Only Apr 10 2015
    Natco Takes Patent Charge Honed in India to U.S. Market Apr 09 2015
    Three-Weeks-Tight Pattern Offers Second Chance To Buy Top Stock Apr 09 2015
    Merck's HCV Combo Drug Gets Two Breakthrough Status - Analyst Blog Apr 09 2015
    The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead -... Apr 09 2015
    Gilead’s $1,000 Pill Is Hard for States to Swallow Apr 08 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK